**S8 Table.** Baseline clinicopathologic and molecular factors and their effects on patients' survival

| Variable | Stratification | Objective response rate Chi-square test p-value | Progression-Free-Survival | | | | Overall survival | | | |
|---|---|---|---|---|---|---|---|---|---|---|
| | | | Univariate analysis | | Multivariate analysis | | Univariate analysis | | Multivariate analysis | |
| | | | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) | p-value | HR (95% CI) |
| Sex | Female vs. male | 0.08 | 0.06 | 2.61 (0.98-6.96) | 0.50 | 1.61 (0.41-6.38) | 0.09 | 2.96 (0.86-10.24) | 0.41 | 2.05 (0.37-11.26) |
| Age (yr) | < 60 vs. ≥ 60 | 1.00 | 0.35 | 1.48 (0.65-3.34) | 0.13 | 2.25 (0.80-6.37) | 0.05 | 3.06 (1.00-9.32) | 0.03 | 4.64 (1.20-18.00) |
| Smoking status | No vs. yes | 0.17 | 0.22 | 1.97 (0.67-5.77) | 0.31 | 2.18 (0.49-9.64) | 0.36 | 1.78 (0.52-6.12) | 0.35 | 2.65 (0.34-20.42) |
| Tumor stage | LS-SCLC vs. ES-SCLC | 0.65 | 0.15 | 1.80 (0.81-3.98) | 0.27 | 1.94 (0.60-6.24) | 0.52 | 1.36 (0.53-3.46) | 0.86 | 0.89 (0.22-3.59) |
| TP53 (B1) | Wild type vs. mutation type | 0.50 | 0.29 | 2.95 (0.40-21.86) | 0.33 | 2.93 (0.33-25.95) | 0.85 | 1.22 (0.16-9.23) | 0.66 | 0.58 (0.05-6.46) |
| RB1 (B1) | Wild type vs. mutation type | 0.67 | 0.60 | 0.81 (0.37-1.76) | 0.19 | 0.54 (0.21-1.36) | 0.44 | 1.44 (0.57-3.69) | 0.54 | 1.44 (0.44-4.73) |
| LRP1B (B1) | Wild type vs. mutation type | 0.67 | 0.27 | 1.54 (0.71-3.35) | 0.28 | 0.59 (0.22-1.53) | 0.15 | 1.96 (0.79-4.86) | 0.29 | 1.85 (0.59-5.78) |
| FAT1 (B1) | Wild type vs. mutation type | 0.13 | 0.33 | 1.58 (0.63-3.94) | 0.11 | 2.88 (0.80-10.37) | 0.03 | 3.52 (1.17-10.63) | 0.02 | 5.66 (0.37-11.26) |

Chi-square test was used to analyze the relationship between these factors and objective response rate. Progression-free survival and overall survival were analyzed using univariate and multivariate Cox regression. $p \leq 0.05$ was considered as significant. CI, confidence interval; HR, hazard ratio.